Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
ScientificWorldJournal. 2015; 2015:414378.S

Abstract

BACKGROUND

Long regimens for the treatment of post-kala-azar dermal leishmaniasis (PKDL) result in noncompliance. A safe, effective, and acceptable regimen for the treatment of PKDL is still to be developed. Miltefosine has been found to be effective in the treatment of Visceral Leishmaniasis (VL). Hence, its efficacy was tested in patients of PKDL.

METHODS

In this exploratory study, 33 patients with PKDL aged 10 years and above were administered miltefosine (50 mg for those weighing < 25 kg or 100 mg in divided doses for those ≥ 25 kg and 2.5 mg per kg for children) for 12 weeks and followed up for one year to find out the efficacy.

RESULTS

Out of 33 patients, 3 patients withdrew consent. Treatment was stopped due to adverse effect in 1 patient. 28 (96.6%) got cured with complete disappearance of lesion while 1 patient (3.4%) failed treatment by protocol analysis.

CONCLUSION

Miltefosine was found to be effective and safe in the treatment of PKDL.

Authors+Show Affiliations

Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.Department of Medicine, All India Institute of Medical Sciences, New Delhi 110029, India.Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

25685839

Citation

Sundar, Shyam, et al. "Efficacy and Safety of Miltefosine in Treatment of Post-kala-azar Dermal Leishmaniasis." TheScientificWorldJournal, vol. 2015, 2015, p. 414378.
Sundar S, Singh A, Chakravarty J, et al. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. ScientificWorldJournal. 2015;2015:414378.
Sundar, S., Singh, A., Chakravarty, J., & Rai, M. (2015). Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. TheScientificWorldJournal, 2015, 414378. https://doi.org/10.1155/2015/414378
Sundar S, et al. Efficacy and Safety of Miltefosine in Treatment of Post-kala-azar Dermal Leishmaniasis. ScientificWorldJournal. 2015;2015:414378. PubMed PMID: 25685839.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. AU - Sundar,Shyam, AU - Singh,Anup, AU - Chakravarty,Jaya, AU - Rai,Madhukar, Y1 - 2015/01/01/ PY - 2014/07/22/received PY - 2014/12/04/revised PY - 2014/12/12/accepted PY - 2015/2/17/entrez PY - 2015/2/17/pubmed PY - 2016/6/3/medline SP - 414378 EP - 414378 JF - TheScientificWorldJournal JO - ScientificWorldJournal VL - 2015 N2 - BACKGROUND: Long regimens for the treatment of post-kala-azar dermal leishmaniasis (PKDL) result in noncompliance. A safe, effective, and acceptable regimen for the treatment of PKDL is still to be developed. Miltefosine has been found to be effective in the treatment of Visceral Leishmaniasis (VL). Hence, its efficacy was tested in patients of PKDL. METHODS: In this exploratory study, 33 patients with PKDL aged 10 years and above were administered miltefosine (50 mg for those weighing < 25 kg or 100 mg in divided doses for those ≥ 25 kg and 2.5 mg per kg for children) for 12 weeks and followed up for one year to find out the efficacy. RESULTS: Out of 33 patients, 3 patients withdrew consent. Treatment was stopped due to adverse effect in 1 patient. 28 (96.6%) got cured with complete disappearance of lesion while 1 patient (3.4%) failed treatment by protocol analysis. CONCLUSION: Miltefosine was found to be effective and safe in the treatment of PKDL. SN - 1537-744X UR - https://www.unboundmedicine.com/medline/citation/25685839/Efficacy_and_safety_of_miltefosine_in_treatment_of_post_kala_azar_dermal_leishmaniasis_ L2 - https://doi.org/10.1155/2015/414378 DB - PRIME DP - Unbound Medicine ER -